Intravascular Ultrasound Market by Product Type (IVUS Catheters, IVUS Consoles), IVUS Modalities (Virtual Histology (VH) IVUS, iMAP IVUS, Integrated Backscatter (IB) IVUS), Indication, Application, End Use, Distribution Channel - Global Forecast 2025-2032
Description
The Intravascular Ultrasound Market was valued at USD 2.50 billion in 2024 and is projected to grow to USD 2.67 billion in 2025, with a CAGR of 6.82%, reaching USD 4.24 billion by 2032.
A strategic introduction that outlines how intravascular ultrasound integrates clinically and commercially to reshape procedural precision and stakeholder priorities
Intravascular ultrasound has transitioned from a specialized imaging adjunct to a central diagnostic and interventional tool that shapes vascular care pathways. This introduction sets the stage by articulating how the modality integrates with interventional cardiology and peripheral vascular practice, the technological building blocks that underpin contemporary systems, and the cross-functional stakeholders-clinicians, procurement teams, and industry executives-who drive adoption decisions.
Clinicians leverage intravascular ultrasound to enhance visualization of vessel morphology, guide device deployment, and optimize procedural outcomes, while device developers focus on miniaturization, image fidelity, and workflow integration. Recent advances in signal processing and catheter design have expanded clinical utility across coronary and peripheral indications. As a result, intravascular ultrasound now plays a meaningful role in pre-procedural planning, intra-procedural guidance, and post-procedural assessment, shifting expectations for procedural precision and long-term patient management.
The introduction also outlines contemporary adoption determinants: interoperability with cath lab systems, training and competency frameworks, and reimbursement alignment. By framing these elements upfront, readers gain a clear understanding of the clinical and commercial levers that shape near-term investments and strategic prioritization within healthcare delivery organizations.
An analysis of the converging technological, clinical, and operational transformations that are redefining intravascular ultrasound practice and product design
The intravascular ultrasound landscape is in the midst of transformative shifts driven by simultaneous technological, clinical, and operational forces. Image processing algorithms now enable higher resolution and faster frame rates, which improve plaque characterization and lumen measurement accuracy. Coupled with refined catheter designs that balance flexibility and acoustic performance, these technical advancements have broadened the range of feasible procedures and reduced procedural friction in complex anatomies.
Clinically, the modality’s role has expanded from diagnostic confirmation to active procedural guidance for interventions such as atherectomy and stent placement. Cross-modality integration with angiography and physiology tools has streamlined decision-making and reduced uncertainty during interventions. At the same time, provider networks are placing greater emphasis on standardized training and credentialing pathways, which supports safer, more consistent use across hospital systems and ambulatory surgical centers.
Operationally, manufacturers and health systems are responding to demands for workflow efficiency and cost-effectiveness by developing portable consoles and single-use catheter strategies that align with ambulatory settings and hybrid operating rooms. Regulatory scrutiny and evidence-generation expectations have also intensified, prompting more rigorous clinical studies and real-world evidence collection. These converging shifts signal an industry accelerating toward devices and services that prioritize clinical outcomes, user experience, and seamless integration into contemporary vascular care pathways.
A comprehensive appraisal of tariff-driven supply chain and procurement dynamics in 2025 that influence manufacturing, distribution, and clinical acquisition practices
Anticipated changes in tariff policy and trade dynamics in 2025 are creating operational and strategic considerations for manufacturers, distributors, and provider organizations that rely on imported components and finished systems. Tariff adjustments can influence supply chain sourcing decisions, prompting device makers to reevaluate procurement strategies for transducers, microelectronics, and catheter materials. In response, some suppliers are assessing nearshoring, supplier diversification, and contract restructuring to mitigate exposure to sudden cost shifts and ensure continuity of supply.
Beyond procurement, tariffs have secondary implications for capital acquisition by hospitals and ambulatory surgical centers. Purchasing cycles for consoles and bundled systems may lengthen as procurement teams incorporate potential duty-related cost variances into budgeting and vendor negotiations. This can delay upgrades or slow replacement timelines, particularly for facilities operating under constrained capital plans. At the same time, distributors and single-source suppliers may explore pricing strategies and contractual protections to shield end users from abrupt cost escalations.
Clinically, the effect of tariffs is indirect but material: constrained investment or delayed technology refreshes can slow the diffusion of best-in-class intravascular ultrasound capabilities into smaller hospitals and outpatient centers. To navigate this environment, stakeholders should prioritize transparent supplier agreements, scenario-based procurement planning, and collaborative risk-sharing arrangements that preserve access to essential imaging tools while maintaining cost discipline.
Insightful segmentation analysis revealing how clinical applications, device types, end-use environments, and procedural roles determine adoption and purchasing priorities
A granular view of segmentation reveals the clinical, technological, and organizational pathways that determine use cases and procurement priorities. When considering application, intravascular ultrasound is actively applied across coronary and peripheral indications; within coronary care it is employed for both acute coronary syndrome and complex chronic total occlusion scenarios, while peripheral practice leverages the modality for peripheral artery disease interventions as well as peripheral venous applications. This distribution of use underscores the modality’s adaptability to distinct vascular territories and procedural imperatives.
Examining product type highlights divergent adoption dynamics between catheters and consoles. Catheter development splits into array catheters, which offer multi-element imaging arrays for enhanced resolution and rapid acquisition, and single element catheters that provide cost-effective, focused imaging. Console platforms divide into portable consoles suited to point-of-care and ambulatory settings, and stationary consoles that target hospital-based cath labs and hybrid operating theaters. These distinctions influence procurement cycles, maintenance support requirements, and capital planning.
End use context further clarifies demand profiles as ambulatory surgical centers, hospitals, and research institutes each place different emphases on throughput, device lifecycle costs, and investigational flexibility. Procedure-based segmentation differentiates diagnostic roles-such as precise lumen measurement and plaque characterization-from guidance roles that support atherectomy adjuncts and stent placement optimization. Together, these segmentation lenses provide a multifaceted understanding of where clinical value is created and how commercial strategies should be tailored to specific user needs.
Regional analysis outlining differentiated adoption drivers and commercialization approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems
Regional dynamics shape technology adoption pathways, reimbursement frameworks, and vendor strategies in meaningful ways. In the Americas, health systems are increasingly focused on outcome-driven technology procurement, which incentivizes solutions that demonstrably improve procedural precision and reduce downstream complications. Private and public payers influence capital allocation decisions, and regional centers of excellence often act as early adopters and dissemination hubs for advanced intravascular imaging techniques.
In Europe, Middle East & Africa, regulatory harmonization, and national-level reimbursement systems create a mosaic of adoption environments. High-volume tertiary centers in major European markets prioritize clinical evidence and integration with cath lab informatics, while emerging markets in the broader region present opportunities for portable consoles and cost-effective catheter models that align with constrained capital environments. Local training and credentialing initiatives are pivotal to scaling use beyond specialized centers.
Asia-Pacific presents heterogeneous but rapidly evolving demand driven by large patient populations, expanding interventional infrastructure, and strong interest in minimally invasive solutions. In many Asia-Pacific markets, investment in catheterization facilities and interventional cardiology training is increasing, which supports broader deployment of intravascular ultrasound. Across regions, differences in procurement cycles, clinical guidelines, and health system financing require tailored commercialization and support strategies from manufacturers and distributors.
An examination of competitive positioning, innovation trajectories, and partnership strategies that determine leadership in intravascular ultrasound solutions
Competitive dynamics in intravascular ultrasound are shaped by a mix of established medical device companies and specialized innovators that emphasize imaging performance, catheter ergonomics, and systems integration. Market leaders pursue strategies that balance product breadth with clinical evidence generation, investing in clinical studies and real-world data collection to validate device performance across coronary and peripheral indications. Partnerships with influential clinical centers and key opinion leaders remain central to accelerating clinical acceptance and refining procedural workflows.
Smaller innovators and new entrants often target niche opportunities, such as high-resolution array catheters or portable console designs that lower the barrier to entry for ambulatory settings. These companies leverage agile development cycles and focused regulatory submissions to introduce differentiated features. Distribution and service networks are critical competitive factors, particularly in regions where localized technical support and training determine long-term procurement relationships.
Strategic alliances between device manufacturers and imaging software firms are also reshaping the competitive landscape, enabling advanced analytics, automated measurement tools, and improved interoperability with cath lab systems. As clinical expectations for precision and workflow efficiency rise, companies that combine robust clinical evidence, comprehensive service models, and seamless integration capabilities will be better positioned to meet the needs of providers across diverse care settings.
Actionable recommendations for leaders to synchronize clinical validation, modular product development, training initiatives, and supply chain resilience to accelerate adoption
Industry leaders seeking to capitalize on intravascular ultrasound opportunities should pursue a coordinated approach that aligns clinical evidence, product design, and market access strategies. First, prioritize rigorous clinical validation that demonstrates clear procedural benefits across both coronary and peripheral applications; targeted clinical studies that address acute coronary syndrome, chronic total occlusion, peripheral artery disease, and venous applications will strengthen adoption arguments with clinicians and payers.
Second, invest in modular product portfolios that span array and single element catheter technologies as well as both portable and stationary console platforms. This dual-path approach enables companies to serve high-throughput hospital cath labs while also addressing the growing ambulatory and hybrid OR segments. Third, establish comprehensive training and credentialing programs that reduce variability in operator performance and accelerate safe deployment across hospitals, ambulatory surgical centers, and research institutes.
Finally, industry leaders should incorporate supply chain resilience into commercial planning by diversifying sourcing, evaluating nearshoring options, and creating flexible contractual terms that mitigate tariff and trade volatility. By combining robust clinical evidence with adaptable product strategies and resilient operations, companies can better navigate complex procurement environments and build durable relationships with healthcare providers.
A transparent multi-method research approach combining stakeholder engagement, literature synthesis, and triangulation to ensure rigorous and reproducible insights
Research for this report was conducted using a multi-method approach that combines targeted primary stakeholder engagement with comprehensive secondary source analysis to ensure depth and accuracy. Primary research included structured interviews and consultations with interventional cardiologists, vascular specialists, procurement professionals, and device engineers to capture real-world practice patterns, procurement drivers, and unmet clinical needs. These qualitative insights were cross-referenced with product specifications and regulatory documentation to validate technology attributes and performance claims.
Secondary research encompassed peer-reviewed clinical literature, regulatory filings, and professional society guidelines to contextualize clinical applications and recommended procedural workflows. Industry publications and technology white papers were examined to map recent device introductions, design trends, and interoperability developments. Throughout the process, triangulation techniques were applied to reconcile differing viewpoints and strengthen the reliability of conclusions.
The synthesis prioritized methodological transparency and reproducibility, documenting interview protocols, inclusion criteria for literature selection, and the timeline of evidence collection. Where appropriate, sensitivity analyses were used to assess how varying assumptions about clinical practice and procurement behaviors could influence strategic implications, ensuring that recommendations remain robust across plausible operational scenarios.
Concluding synthesis that underscores intravascular ultrasound as a precision enabler and highlights adoption determinants across clinical, operational, and regional dimensions
This analysis culminates in a concise set of conclusions that highlight intravascular ultrasound as a critical enabler of procedural precision and clinical decision-making across coronary and peripheral vascular care. Technological progress in catheter design, imaging resolution, and system interoperability has expanded the modality’s utility from diagnostic assessment to active procedural guidance, particularly for complex interventions such as chronic total occlusion and atherectomy-assisted procedures.
Adoption patterns are influenced by an interplay of clinical evidence, procurement dynamics, and regional healthcare infrastructure. Hospitals, ambulatory surgical centers, and research institutes each present distinct requirements that favor specific combinations of catheter technology and console deployment. Concurrently, supply chain and policy variables, including tariff considerations, can affect procurement timing and capital allocation, underscoring the importance of resilient sourcing and flexible commercial models.
Looking forward, success will favor stakeholders who align product innovation with demonstrable clinical outcomes, invest in operator training, and structure competitive service models that support rapid integration into existing workflows. By prioritizing these elements, both manufacturers and provider organizations can accelerate value realization from intravascular ultrasound while managing operational and regulatory complexity.
Note: PDF & Excel + Online Access - 1 Year
A strategic introduction that outlines how intravascular ultrasound integrates clinically and commercially to reshape procedural precision and stakeholder priorities
Intravascular ultrasound has transitioned from a specialized imaging adjunct to a central diagnostic and interventional tool that shapes vascular care pathways. This introduction sets the stage by articulating how the modality integrates with interventional cardiology and peripheral vascular practice, the technological building blocks that underpin contemporary systems, and the cross-functional stakeholders-clinicians, procurement teams, and industry executives-who drive adoption decisions.
Clinicians leverage intravascular ultrasound to enhance visualization of vessel morphology, guide device deployment, and optimize procedural outcomes, while device developers focus on miniaturization, image fidelity, and workflow integration. Recent advances in signal processing and catheter design have expanded clinical utility across coronary and peripheral indications. As a result, intravascular ultrasound now plays a meaningful role in pre-procedural planning, intra-procedural guidance, and post-procedural assessment, shifting expectations for procedural precision and long-term patient management.
The introduction also outlines contemporary adoption determinants: interoperability with cath lab systems, training and competency frameworks, and reimbursement alignment. By framing these elements upfront, readers gain a clear understanding of the clinical and commercial levers that shape near-term investments and strategic prioritization within healthcare delivery organizations.
An analysis of the converging technological, clinical, and operational transformations that are redefining intravascular ultrasound practice and product design
The intravascular ultrasound landscape is in the midst of transformative shifts driven by simultaneous technological, clinical, and operational forces. Image processing algorithms now enable higher resolution and faster frame rates, which improve plaque characterization and lumen measurement accuracy. Coupled with refined catheter designs that balance flexibility and acoustic performance, these technical advancements have broadened the range of feasible procedures and reduced procedural friction in complex anatomies.
Clinically, the modality’s role has expanded from diagnostic confirmation to active procedural guidance for interventions such as atherectomy and stent placement. Cross-modality integration with angiography and physiology tools has streamlined decision-making and reduced uncertainty during interventions. At the same time, provider networks are placing greater emphasis on standardized training and credentialing pathways, which supports safer, more consistent use across hospital systems and ambulatory surgical centers.
Operationally, manufacturers and health systems are responding to demands for workflow efficiency and cost-effectiveness by developing portable consoles and single-use catheter strategies that align with ambulatory settings and hybrid operating rooms. Regulatory scrutiny and evidence-generation expectations have also intensified, prompting more rigorous clinical studies and real-world evidence collection. These converging shifts signal an industry accelerating toward devices and services that prioritize clinical outcomes, user experience, and seamless integration into contemporary vascular care pathways.
A comprehensive appraisal of tariff-driven supply chain and procurement dynamics in 2025 that influence manufacturing, distribution, and clinical acquisition practices
Anticipated changes in tariff policy and trade dynamics in 2025 are creating operational and strategic considerations for manufacturers, distributors, and provider organizations that rely on imported components and finished systems. Tariff adjustments can influence supply chain sourcing decisions, prompting device makers to reevaluate procurement strategies for transducers, microelectronics, and catheter materials. In response, some suppliers are assessing nearshoring, supplier diversification, and contract restructuring to mitigate exposure to sudden cost shifts and ensure continuity of supply.
Beyond procurement, tariffs have secondary implications for capital acquisition by hospitals and ambulatory surgical centers. Purchasing cycles for consoles and bundled systems may lengthen as procurement teams incorporate potential duty-related cost variances into budgeting and vendor negotiations. This can delay upgrades or slow replacement timelines, particularly for facilities operating under constrained capital plans. At the same time, distributors and single-source suppliers may explore pricing strategies and contractual protections to shield end users from abrupt cost escalations.
Clinically, the effect of tariffs is indirect but material: constrained investment or delayed technology refreshes can slow the diffusion of best-in-class intravascular ultrasound capabilities into smaller hospitals and outpatient centers. To navigate this environment, stakeholders should prioritize transparent supplier agreements, scenario-based procurement planning, and collaborative risk-sharing arrangements that preserve access to essential imaging tools while maintaining cost discipline.
Insightful segmentation analysis revealing how clinical applications, device types, end-use environments, and procedural roles determine adoption and purchasing priorities
A granular view of segmentation reveals the clinical, technological, and organizational pathways that determine use cases and procurement priorities. When considering application, intravascular ultrasound is actively applied across coronary and peripheral indications; within coronary care it is employed for both acute coronary syndrome and complex chronic total occlusion scenarios, while peripheral practice leverages the modality for peripheral artery disease interventions as well as peripheral venous applications. This distribution of use underscores the modality’s adaptability to distinct vascular territories and procedural imperatives.
Examining product type highlights divergent adoption dynamics between catheters and consoles. Catheter development splits into array catheters, which offer multi-element imaging arrays for enhanced resolution and rapid acquisition, and single element catheters that provide cost-effective, focused imaging. Console platforms divide into portable consoles suited to point-of-care and ambulatory settings, and stationary consoles that target hospital-based cath labs and hybrid operating theaters. These distinctions influence procurement cycles, maintenance support requirements, and capital planning.
End use context further clarifies demand profiles as ambulatory surgical centers, hospitals, and research institutes each place different emphases on throughput, device lifecycle costs, and investigational flexibility. Procedure-based segmentation differentiates diagnostic roles-such as precise lumen measurement and plaque characterization-from guidance roles that support atherectomy adjuncts and stent placement optimization. Together, these segmentation lenses provide a multifaceted understanding of where clinical value is created and how commercial strategies should be tailored to specific user needs.
Regional analysis outlining differentiated adoption drivers and commercialization approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems
Regional dynamics shape technology adoption pathways, reimbursement frameworks, and vendor strategies in meaningful ways. In the Americas, health systems are increasingly focused on outcome-driven technology procurement, which incentivizes solutions that demonstrably improve procedural precision and reduce downstream complications. Private and public payers influence capital allocation decisions, and regional centers of excellence often act as early adopters and dissemination hubs for advanced intravascular imaging techniques.
In Europe, Middle East & Africa, regulatory harmonization, and national-level reimbursement systems create a mosaic of adoption environments. High-volume tertiary centers in major European markets prioritize clinical evidence and integration with cath lab informatics, while emerging markets in the broader region present opportunities for portable consoles and cost-effective catheter models that align with constrained capital environments. Local training and credentialing initiatives are pivotal to scaling use beyond specialized centers.
Asia-Pacific presents heterogeneous but rapidly evolving demand driven by large patient populations, expanding interventional infrastructure, and strong interest in minimally invasive solutions. In many Asia-Pacific markets, investment in catheterization facilities and interventional cardiology training is increasing, which supports broader deployment of intravascular ultrasound. Across regions, differences in procurement cycles, clinical guidelines, and health system financing require tailored commercialization and support strategies from manufacturers and distributors.
An examination of competitive positioning, innovation trajectories, and partnership strategies that determine leadership in intravascular ultrasound solutions
Competitive dynamics in intravascular ultrasound are shaped by a mix of established medical device companies and specialized innovators that emphasize imaging performance, catheter ergonomics, and systems integration. Market leaders pursue strategies that balance product breadth with clinical evidence generation, investing in clinical studies and real-world data collection to validate device performance across coronary and peripheral indications. Partnerships with influential clinical centers and key opinion leaders remain central to accelerating clinical acceptance and refining procedural workflows.
Smaller innovators and new entrants often target niche opportunities, such as high-resolution array catheters or portable console designs that lower the barrier to entry for ambulatory settings. These companies leverage agile development cycles and focused regulatory submissions to introduce differentiated features. Distribution and service networks are critical competitive factors, particularly in regions where localized technical support and training determine long-term procurement relationships.
Strategic alliances between device manufacturers and imaging software firms are also reshaping the competitive landscape, enabling advanced analytics, automated measurement tools, and improved interoperability with cath lab systems. As clinical expectations for precision and workflow efficiency rise, companies that combine robust clinical evidence, comprehensive service models, and seamless integration capabilities will be better positioned to meet the needs of providers across diverse care settings.
Actionable recommendations for leaders to synchronize clinical validation, modular product development, training initiatives, and supply chain resilience to accelerate adoption
Industry leaders seeking to capitalize on intravascular ultrasound opportunities should pursue a coordinated approach that aligns clinical evidence, product design, and market access strategies. First, prioritize rigorous clinical validation that demonstrates clear procedural benefits across both coronary and peripheral applications; targeted clinical studies that address acute coronary syndrome, chronic total occlusion, peripheral artery disease, and venous applications will strengthen adoption arguments with clinicians and payers.
Second, invest in modular product portfolios that span array and single element catheter technologies as well as both portable and stationary console platforms. This dual-path approach enables companies to serve high-throughput hospital cath labs while also addressing the growing ambulatory and hybrid OR segments. Third, establish comprehensive training and credentialing programs that reduce variability in operator performance and accelerate safe deployment across hospitals, ambulatory surgical centers, and research institutes.
Finally, industry leaders should incorporate supply chain resilience into commercial planning by diversifying sourcing, evaluating nearshoring options, and creating flexible contractual terms that mitigate tariff and trade volatility. By combining robust clinical evidence with adaptable product strategies and resilient operations, companies can better navigate complex procurement environments and build durable relationships with healthcare providers.
A transparent multi-method research approach combining stakeholder engagement, literature synthesis, and triangulation to ensure rigorous and reproducible insights
Research for this report was conducted using a multi-method approach that combines targeted primary stakeholder engagement with comprehensive secondary source analysis to ensure depth and accuracy. Primary research included structured interviews and consultations with interventional cardiologists, vascular specialists, procurement professionals, and device engineers to capture real-world practice patterns, procurement drivers, and unmet clinical needs. These qualitative insights were cross-referenced with product specifications and regulatory documentation to validate technology attributes and performance claims.
Secondary research encompassed peer-reviewed clinical literature, regulatory filings, and professional society guidelines to contextualize clinical applications and recommended procedural workflows. Industry publications and technology white papers were examined to map recent device introductions, design trends, and interoperability developments. Throughout the process, triangulation techniques were applied to reconcile differing viewpoints and strengthen the reliability of conclusions.
The synthesis prioritized methodological transparency and reproducibility, documenting interview protocols, inclusion criteria for literature selection, and the timeline of evidence collection. Where appropriate, sensitivity analyses were used to assess how varying assumptions about clinical practice and procurement behaviors could influence strategic implications, ensuring that recommendations remain robust across plausible operational scenarios.
Concluding synthesis that underscores intravascular ultrasound as a precision enabler and highlights adoption determinants across clinical, operational, and regional dimensions
This analysis culminates in a concise set of conclusions that highlight intravascular ultrasound as a critical enabler of procedural precision and clinical decision-making across coronary and peripheral vascular care. Technological progress in catheter design, imaging resolution, and system interoperability has expanded the modality’s utility from diagnostic assessment to active procedural guidance, particularly for complex interventions such as chronic total occlusion and atherectomy-assisted procedures.
Adoption patterns are influenced by an interplay of clinical evidence, procurement dynamics, and regional healthcare infrastructure. Hospitals, ambulatory surgical centers, and research institutes each present distinct requirements that favor specific combinations of catheter technology and console deployment. Concurrently, supply chain and policy variables, including tariff considerations, can affect procurement timing and capital allocation, underscoring the importance of resilient sourcing and flexible commercial models.
Looking forward, success will favor stakeholders who align product innovation with demonstrable clinical outcomes, invest in operator training, and structure competitive service models that support rapid integration into existing workflows. By prioritizing these elements, both manufacturers and provider organizations can accelerate value realization from intravascular ultrasound while managing operational and regulatory complexity.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of 3D and real-time volumetric IVUS systems by leading hospitals
- 5.2. Integration of artificial intelligence algorithms for automated plaque characterization using IVUS
- 5.3. Development of hybrid IVUS-OCT catheters for comprehensive coronary lesion assessment
- 5.4. Growing utilization of IVUS guidance in complex chronic total occlusion interventions
- 5.5. Expansion of IVUS-compatible fiber-optic sensors enabling higher resolution imaging fidelity
- 5.6. Partnerships between device manufacturers and software firms to enhance IVUS image analysis
- 5.7. Increasing reimbursement approvals driving broader clinical adoption of IVUS devices
- 5.8. Focus on miniaturized IVUS catheters for peripheral vascular and neurovascular applications
- 5.9. Shift toward IVUS-guided PCI as a standard of care in complex coronary interventions, driven by outcome data from large multicenter trials
- 5.10. Regulatory clearances of next-generation solid-state IVUS consoles that streamline workflow with faster pullback and improved user interfaces
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Intravascular Ultrasound Market, by Product Type
- 8.1. IVUS Catheters
- 8.1.1. Array Catheters
- 8.1.2. Single Element Catheters
- 8.2. IVUS Consoles
- 8.2.1. Portable Consoles
- 8.2.2. Cart-Based Consoles
- 9. Intravascular Ultrasound Market, by IVUS Modalities
- 9.1. Virtual Histology (VH) IVUS
- 9.2. iMAP IVUS
- 9.3. Integrated Backscatter (IB) IVUS
- 10. Intravascular Ultrasound Market, by Indication
- 10.1. Coronary Artery Disease
- 10.2. Peripheral Arterial Disease
- 10.3. Structural Heart Disease
- 10.4. Congenital Heart Disease
- 11. Intravascular Ultrasound Market, by Application
- 11.1. Coronary
- 11.1.1. Acute Coronary Syndrome
- 11.1.2. Chronic Total Occlusion
- 11.2. Peripheral
- 11.2.1. Peripheral Artery Disease
- 11.2.2. Peripheral Venous Applications
- 12. Intravascular Ultrasound Market, by End Use
- 12.1. Ambulatory Surgical Centers
- 12.2. Hospitals
- 12.3. Research Institutes
- 13. Intravascular Ultrasound Market, by Distribution Channel
- 13.1. Direct Sales
- 13.2. Distributor Sales
- 13.3. Online & E-Procurement Platforms
- 14. Intravascular Ultrasound Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Intravascular Ultrasound Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Intravascular Ultrasound Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Boston Scientific Corporation
- 17.3.2. Koninklijke Philips N.V.
- 17.3.3. Abbott Laboratories
- 17.3.4. ACIST Medical Systems by Bracco S.p.A.
- 17.3.5. Avinger, Inc.
- 17.3.6. B. Braun SE
- 17.3.7. Canon Medical Systems Corporation
- 17.3.8. Conavi Medical Inc.
- 17.3.9. Esaote S.p.A
- 17.3.10. Fujifilm Corporation
- 17.3.11. GE HealthCare Technologies Inc.
- 17.3.12. GERMITEC
- 17.3.13. Hologic, Inc.
- 17.3.14. Infraredx, Inc. by Nipro Company
- 17.3.15. Johnson & Johnson
- 17.3.16. Medtronic plc
- 17.3.17. Samsung Electronics Co., Ltd
- 17.3.18. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
- 17.3.19. Siemens AG
- 17.3.20. SonoScape Medical Corp.
- 17.3.21. Stryker Corporation
- 17.3.22. Terumo Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
